Key Lab on Etiological Epidemiology, Harbin Medical University, Harbin, China.
Clin Rheumatol. 2010 Apr;29(4):357-62. doi: 10.1007/s10067-009-1311-z. Epub 2010 Jan 28.
The purpose is to investigate the effects of chondroitin sulfate and glucosamine on adult patients with Kaschin-Beck disease (KBD). A total of 80 patients, aged over 40 years, were randomized into two groups receiving either 1,600 mg oral mixture of chondroitin sulfate and glucosamine or placebo twice daily for 8 months. Posteroanterior radiographs of bilateral knee in full extension were taken at enrollment and after 8 months. Mean joint-space width of the assigned six points on the tibiofemoral joint compartment was measured by a graduated magnifying lens. The mean joint space decreased significantly in the placebo group (4.3 +/- 1.09 versus 4.1 +/- 1.07 mm, P < 0.0001) after 8 months and was unchanged in the experimental group (P = 0.51). There was no statistical significance in the mean joint space between two groups at baseline and follow-up (P = 0.65 and P = 0.84, respectively). But the overall mean change in joint space was significant between the two groups (P < 0.0001). Knee joint space of the experimental group narrowed slowly compared to the control group. Therefore, chondroitin sulfate and glucosamine might play a protective role in preserving articular cartilage and provide evidence for therapeutic drugs in adult patients with KBD.
研究硫酸软骨素和氨基葡萄糖对成人 Kaschin-Beck 病（KBD）患者的影响。共 80 例年龄大于 40 岁的患者，随机分为两组，分别每天两次口服 1600mg 硫酸软骨素和氨基葡萄糖混合物或安慰剂，疗程为 8 个月。在入组时和 8 个月后，拍摄双侧膝关节完全伸展的后前位 X 线片。通过带刻度的放大镜测量胫骨股骨关节腔内指定的 6 个点的平均关节间隙宽度。8 个月后，安慰剂组的平均关节间隙明显减小（4.3 ± 1.09 毫米比 4.1 ± 1.07 毫米，P < 0.0001），而实验组无变化（P = 0.51）。两组间基线和随访时的平均关节间隙无统计学差异（分别为 P = 0.65 和 P = 0.84）。但两组间的平均关节间隙总变化有显著差异（P < 0.0001）。与对照组相比，实验组膝关节间隙狭窄缓慢。因此，硫酸软骨素和氨基葡萄糖可能在保护关节软骨方面发挥保护作用，并为 KBD 成年患者提供治疗药物的证据。
